The Consumer Is Cracking. The Market Hasn't Noticed Yet.
Sector rotation playbook: where to hide when the discretionary trade unwinds. Plus: trimming DELL and LQDA on the rule that respects the trend
Photo by Kit Suman on Unsplash
Weekly Read — Macro, Sectors, Portfolios
🌍 Macro
M2 liquidity is rising again. Financial conditions look healthy. Inflation forecasts for June 2026 are pointing down. Oil is falling. The 10-year is falling. All green.
With Iran likely off the board, rates probably go nowhere for a while. That beats the consensus call of higher rates by year-end. Backdrop stays positive for risk assets — but geopolitics can flip it fast.
📊 Index Read
SPX closed -1.95% on the week. MACD positive, histogram fading. RSI down to 60 from 70. Momentum is cooling, not breaking. Stage 2 intact, with some weekly chart deterioration — mostly Semis and Tech doing the damage.
🔄 Sectors & Themes
If the ceasefire holds (base case):
Buy: XLV +6.85% 1W (Healthcare breaking out from 6 months of underperformance — the contrarian rotation). XBI +6.53% 1W, +13.67% 1M (Biotech: rate-sensitive plus M&A waking up). ITB +7.77% 1W (Homebuilders on lower rates). JETS +7.42% 1W (Airlines, direct fuel beneficiary). XLI (Industrials, broad capex cycle).
Avoid: XLE -8.70% 3M (no catalyst). ITA (defense premium bled out). URA -14%, URNM -13% 1M (momentum broken). AIQ down from +33% 3M (topping signature). Broad consumer discretionary.
Tech & Semis
SMH dropped -8.57% in one week off a +56% 3M run. Looks like a top. It’s digestion, not regime change.
Why the bull case still holds:
Net/Gross PP&E ratio at 10-year high, driven by AI infra capex
Adjusted EPS estimates revised 15% → 19% for 2026, 24% for 2026-27
Hyperscaler capex is multi-year, not cyclical
Don’t chase SMH/XLK here. Wait for the 10W MA test. Rotation out of mega-cap semis likely runs 4-8 weeks. The 6-12 month trend stays up.
The Consumer Credit Crack — the signal nobody is pricing
Credit card delinquencies up 7 straight quarters. Auto delinquencies at all-time highs. Student loan delinquencies spiked to 10.34% — wiping out 21 quarters of decline. Consumer confidence at 93 vs 120-130 pre-pandemic.
Corporate credit, meanwhile, is the healthiest since 2021. This split is the defining feature of the cycle.
What to do about it:
Avoid broad consumer discretionary. XLY -8.15% 6M says the market is catching on.
Overweight businesses whose customer is corporate, not consumer — industrials, capex names, B2B software, healthcare. That’s where 2026 earnings growth lives.
Avoid sub-prime financials. XLF looks fine at the index level, but credit card, auto, and consumer finance lenders are walking into a deterioration cycle.
Staples (XLP) are no longer the safe haven. Even staples customers are trading down. Discount retail and value-grocery are the relative winners.
🎯 Bottom Line
Bullish structurally. Expect chop. Buy dips. Best new entries: XLV, XBI, ITB, JETS, XLI. Trim/avoid: XLE, ITA, URA, URNM, AIQ, XLY. Hold and buy dips in core Tech/Semis (XLK, SMH) — don’t chase. Hidden risk: consumer credit.
This is a late-stage Growth Bull, not a top.
💼 10X Momentum Portfolio
Stopped out: GENI –20%
Took the full stop. Position moved against me right after entry, never gave the thesis room. Friday it ripped +15% off the lows. That’s the methodology — most trades lose small, a few win big. The tape doesn’t care about your timing.
New entry: RYTM (Rhythm Pharmaceuticals)
Buy stop order at $110, 25 shares, GTC one week. No fill, no trade. if triggered, first Stop Loss level at $89.9
What RYTM does
Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focused on treating rare neuroendocrine diseases of obesity using medicines that target the MC4R pathway. It has a commercial foundation built around IMCIVREE (setmelanotide), which has approvals/authorizations and reimbursed access or named-patient sales in 25+ countries, and it is also advancing additional MC4R agonists (including bivamelagon and RM-718) across multiple obesity-related indications.
Metrics
Forward revenue growth +60%
Revenue surprise Positive
TTM revenue $174M → $190M → $217M
Adjusted ROA -3% (2026) → +21% (2027)
Earnings margins -12% (2026) → +50% (2027)
Textbook transition story. Profitability inflection in ‘27. Top-line already compounding. Not a Core Compounder — this is a momentum trade. Entry confirmation does the work; the stop defines the risk.
The buy stop above current price is the point. The market has to prove the breakout before I commit.
💼 10X Easy Doubles Portfolio
Portfolio at a glance: +22.6% on deployed capital ($27.4K → $33.6K). $6,184 unrealised. Beating SP500 by ~10 points since inception. 11 positions open, 4 slots free.
The book is doing what it’s supposed to do. Four names carry the P&L — DELL +128%, LQDA +110%, ZVRA +42%, HIMS +30%. AXSM is working, slowly. Four are quietly underwater inside normal noise (RDDT, LEGN, UPST, NTNX). Two need a re-read: ARDX -22% and ZETA -20%.
One thing to be clear about: 95% of the unrealised P&L sits in DELL and LQDA. That’s not a flaw — adjusted accounting plus technical entry is supposed to produce skewed outcomes. But it does mean the headline number is fragile if either rolls over. Which is exactly why we trim now.
Trimming LQDA (⅓) and DELL (½). Same rule for both: weekly RSI >85 triggers a partial trim, then the rest trails on the 10-week MA instead of the 30-week.
LQDA — trim ⅓ at market Monday
Entry ~$37. Now $78.17 (+110%). Weekly RSI 86.04 — trigger active. MACD still expanding (10.46 vs 7.15). New trail: 10W MA at $57.98.
Why ⅓ and not ½: MACD is still expanding, the RS line vs SPX just broke out vertically, SCTR at 98.1. The trend is accelerating, not topping. RSI 86 says take some off. The rest of the tape says don’t take too much off.
DELL — trim ½ at market Monday
Entry ~$175. Now $399.49 (+128%). Recent high $469.47 — already -15% off. Weekly RSI 79.52 (peaked higher two weeks ago). MACD histogram compressing — first warning bar. New trail: 10W MA at $324.38.
DELL is the more urgent trim. The clean RSI >85 signal fired on the run to $469 and I didn’t act. That’s the trade I owe back to the system. Price is 15% off the high. MACD histogram printed its first compression bar. The stock closed -2.44% Friday on heavy volume. The setup that drove the move is showing the first signs of exhaustion.
The rule, restated:
Weekly RSI >85 → partial trim. Size to MACD: ⅓ if expanding, ½ if compressing. Trail the rest on the 10-week MA.
One rule. Mechanical. Repeatable. Designed to keep the right tail intact while taking risk off.
After Monday: ~$3,500 realised across both. Remainders on tight 10W trails. 4 slots still open, no rush to deploy — let the trims breathe before adding new exposure.
The system is doing its job. Big winners, take chips off the table, let the rest ride on a rule that respects the trend.
Not investment advice. Do your own research and consult a licensed advisor before acting.